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Patient Oriented and Performance Based Outcomes following Knee Autologous 1 
Chondrocyte Implantation: a time line for the 1st year of recovery 2 
 3 
Context: It is well established that autologous chondrocyte implantation(ACI) can require 4 
extended recovery postoperatively; however, little information exists to provide clinicians and 5 
patients with a timeline for anticipated function during the first year following ACI.  Objective: 6 
To document the recovery of functional performance of activities of daily living following ACI. 7 
Patients:  ACI Patients(n=48, 29 males,  35.1±8.0yrs).  Intervention: All patients completed 8 
functional tests (Weight Bearing Squat, Walk Across, Sit-to-Stand, Step Up/Over, and Forward 9 
Lunge) using the NeuroCom Long Forceplate(Clackamas, OR), and completed patient reported 10 
outcome measures (IKDC, Lysholm, WOMAC, and SF-36) preoperatively and 3, 6, and 12 11 
months postoperatively. Main Outcome Measures: A covariance pattern model was used to 12 
compare performance and self-reported outcome across time and provide a time line for 13 
functional recovery following ACI.  Results:  Participants demonstrated significant 14 
improvement in Walk Across stride length from baseline(42.0±8.9 % height) at 6 (46.8±8.1%) 15 
and 12 months(46.6±7.6%). Weight bearing on the involved limb during squatting at 30°, 60°, 16 
and 90° was significantly less at 3 months as compared to pre-surgery.  Step Up/Over time was 17 
significantly slower at 3 months(1.67±0.69) compared to baseline(1.49±0.33s), 6 18 
months(1.51±0.36s), and 12 months(1.40±0.26s).  Step Up/Over, lift-up index was increased 19 
from baseline(41.0±11.3 %BW) at 3 (45.0±11.7%BW) 6 (47.0±11.3 %BW) and 12 20 
months(47.3±11.6 %BW). Forward lunge time was decreased at 3 months(1.51±0.44s) compared 21 
to baseline(1.39±0.43s), 6 months(1.32±0.046s), and 12 months(1.27±0.056).  Similarly, 22 
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Forward Lunge impact force was decreased at 3 months(22.2±1.4 %BW) compared to baseline 23 
(25.4±1.5 %BW).  The WOMAC demonstrated significant improvements at 3 months. All 24 
patient reported outcomes were improved from baseline at 6 and 12 months post-surgery.  25 
Conclusions:  Patients’ perceptions of improvements may outpace physical changes in function.  26 
Decreased function for at least the first 3 months following ACI should be anticipated, and 27 
improvement in performance of tasks requiring weight bearing knee flexion, such as squatting, 28 
going down stairs, or lunging, may not occur for a year or longer following surgery.  29 
 30 
 31 
 Autologous chondrocyte implantation (ACI)
1
 has become an acceptable and common 32 
treatment approach for the management of symptomatic articular cartilage defects.
2
  As research 33 
regarding ACI has advanced sizable efforts have been made to evaluate both disease and patient 34 
oriented outcomes following ACI.  Numerous studies have evaluated the utilization of patient 35 
reported outcome measures (PROs) to document the recovery of function and return to activity 36 
following ACI.
3-5
  Meta-analyses of more than 43 studies have revealed large effect sizes 37 
demonstrating significant improvement for a variety of PRO scores following ACI.
5
  PROs 38 
provide reliable and valid information regarding patients’ perceived function and health related 39 
quality of life (HRQL).
6-13
  An alternative to PROs is the use of performance based assessments 40 
(PBAs) to document outcomes.  PBAs provide a direct, objective measure of patient function and 41 
involve measures of performance such as time, distance, or force for specified tasks or 42 
movements.  The relationship between PROs and PBAs has previously been reported as low to 43 
moderate among a variety of knee patients.
14-19
  This discordance may be due in part to the 44 
strong influence perceived pain may have on PROs.  For example, PRO scores may increase 45 
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even in the absence of improved function if a patient’s pain has been resolved.19-22  Recent 46 
research involving total joint arthroplasty patients has provided further support for the inclusion 47 
of PBAs as part of a detailed outcomes assessment protocol.
18-20
   Combining PROs with PBAs 48 
may provide a more complete picture of clinical outcomes after ACI than the utilization of either 49 
type of outcome in isolation. 50 
Few studies have utilized PBAs to document the return of function following ACI.   Most 51 
of those that have, have either examined very low demand activity such as the 6 minute walk 52 
test,
23-27
 or very high demand activity via the single-limb hop.
28
  No known studies have 53 
examined the timeline for return to function following ACI using low to moderate demand PBAs 54 
that recreate the demands and stresses of common activities of daily living such as squatting, 55 
rising from sitting, or going up and down stairs, in addition to walking.  A description of 56 
functional recovery during the first year following ACI is imperative to provide evidence for 57 
prescription of appropriate patient education, rehabilitation protocols, and understanding of the 58 
recovery process.  Therefore, the purpose of this study was to document serial changes in knee 59 
function over one year following ACI using both PROs and PBAs.  It was hypothesized that 60 
PROs would demonstrate significant improvement from baseline at all postoperative time points.  61 
It was also hypothesized that PBA measures for walking, rising from sitting, stepping up/over, 62 
and lunging would demonstrate no improvements at the 3 month time point followed by 63 
progressive improvement at 6 months and 12 months as compared to baseline measures of 64 
function.   65 
 66 
METHODS 67 
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Patients 68 
 Between July 2008 and July 2011 patients were prospectively recruited from an active 69 
cartilage center.  Inclusion criteria were planned ACI surgery to the medial or lateral femoral 70 
condyle, trochlea, or patella; willingness to participate; no uncorrectable contraindications to 71 
ACI such as extensive degenerative joint disease, insufficient meniscus, or unstable knee; and 72 
ability to ambulate without use of assistive devices.  There were no exclusions based on limb 73 
malalignment if the malalignment was corrected prior to or at the time of surgery via high tibial 74 
osteotomy or tibial tubercle transfer.  Similarly, patients undergoing concomitant or staged 75 
ligament reconstruction to correct joint instability were also eligible for study participation.   76 
A total of 50 patients (31 males, 19 females, 35.0±7.9 yrs, 180.34±30.7 cm, 92.0±20.6 77 
kg) agreed to participate.  During the enrollment period four patients were invited to take part of 78 
the study, but declined to participate resulting in an enrollment rate of 93% of eligible patients.  79 
Of the enrolled patients 24 underwent ACI to the patellofemoral joint with a tibial tubercle 80 
transfer and the remaining 26 underwent ACI to the medial femoral condyle, of which 4 also had 81 
a concomitant high tibial osteotomy and 2 underwent concomitant meniscal transplantation.  82 
Mean number of defects treated per patient were 1.5 ± 0.6 with an average treatment area of 8.7 83 
± 6.8 cm
2
 (range 1.96 to 39.0 cm
2
).  All participants signed a university approved IRB consent 84 
form at the time of enrollment. 85 
Procedures 86 
Surgical Procedures and Rehabilitation 87 
 All patients underwent a two-step ACI procedure performed by the same surgeon (CL).  88 
During the first procedure a limited chondroplasty was performed and the lesion was evaluated 89 
arthroscopically.  At this time a biopsy was obtained from the intracondylar notch (100 to 200 90 
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mg cartilage).  This sample was sent to a commercial laboratory where it was cultured and 91 
expanded (Carticel, Genzyme Corp, Cambridge, MA).  In a second surgical procedure 92 
chondrocyte implantation was performed using a mini-arthrotomy.  First the defect or defects 93 
were prepared using a curette to debride down to the subchondral plate with stable edges.  A type 94 
I/III collagen membrane (Bio-Gide 
(R)
, Geistlich Biomaterials, Wohousen, Switzerland) was 95 
shaped to match the defect.  Sutures and fibrin glue (Tisseel, Baxter Healthcare Corp., Deerfield, 96 
IL) were used to adhere the membrane over the defect to form a water tight seal.  The 97 
chondrocytes in suspension were then injected beneath the membrane into the defect through a 98 
small portal remaining at the edge of the collagen membrane.  The portal was then closed and 99 
sealed with sutures and additional fibrin glue. 100 
 All patients followed standardized rehabilitation protocols following surgery with 101 
considerations for defect location and concomitant procedures.
29
  All patients were braced in full 102 
extension and were non-weight bearing for 2 weeks postoperatively.  Toe-touch weight bearing 103 
was permitted from 2 to 4 weeks with partial weight bearing from 4 to 6 weeks and progression 104 
to full weight bearing between weeks 6 to 12.  Continuous passive motion was prescribed for all 105 
patients for 6 to 8 hours per day for 6 weeks.  For defects in the tibiofemoral joint, knee braces 106 
were gradually unlocked between 2 to 4 weeks as quadriceps control was gained.  For defects to 107 
the patellofemoral joint, knees were braced in full extension for weight bearing through 4 weeks 108 
postoperative and then were gradually unlocked as quadriceps control was gained between weeks 109 
4 and 6.  Once good quadriceps control was gained all patients were transitioned to a hinged 110 
knee sleeve.  All patients were recommended to abstain from high intensity cutting or pivoting 111 
activity until at least 12 months post ACI. 112 
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Patient Reported Outcomes 113 
 The PROs used in this study were the Medical Outcomes Study – 36 Item Short Form 114 
Health Survey Physical Component Scales (SF-36 PCS),
11, 30, 31
 the Western Ontario and 115 
McMaster Osteoarthritis Index (WOMAC),
10
 the International Knee Documentation Committee 116 
(IKDC) Subjective Knee Evaluation Form,
7
 and the Lysholm scale.
32
  The SF-36,
13
 IKDC,
13
 117 
Lysholm, 
8
 and WOMAC
8, 13
 have all been evaluated for reliability among cartilage patients.  A 118 
researcher independent of the treating physician reviewed each instrument with the patients and 119 
was available to answer any questions they may have had.  All PROs were completed at the 120 
following time points: prior to implantation (preoperation), 3 months, 6 months, and 12 months 121 
post-surgery. 122 
Performance Based Assessments 123 
 At each time point after completing PROs each participant completed a series of 6 PBAs 124 
in a musculoskeletal laboratory setting.   All PBAs were completed using the NeuroCom Balance 125 
Master
®
 and long forceplate (NeuroCom International, Clackamas, OR).   This is a commercially 126 
available system designed both as a training and evaluation tool for function and balance tasks, 127 
and it has the ability to provide immediate feedback to clinicians and patients regarding quality 128 
of task performance for a variety of activities of daily living (ADLs).
33
  The only exposure study 129 
participants had with the long foreplate was for research testing purposes and they were not 130 
provided feedback during testing. 131 
The long forceplate consists of a 45.72 cm x 152.40 cm force plate with data sampled at 132 
100 Hz and a personal computer equipped with data capture software (Balance Master ver. 8.1). 133 
These functional tasks were selected because of their direct relationship to activities of daily 134 
living and the feasibility of patients being able to complete the task at each testing time point 135 
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(Table 1). Tests were completed in the order presented at all time points.  This order was 136 
subjectively determined during pilot testing to be from least to most demanding. All testing was 137 
administered by the same investigator (JSH).  For all single limb tests the uninvolved limb was 138 
tested first. Three successful trials of each task were performed (except for the Weight Bearing 139 
Squat which consisted of a single trial at each joint angle).  Approximately 15s of rest was 140 
permitted between each trial and 30s of rest between each task.  For the purposes of this 141 
manuscript all outcome variables are identified using the names assigned to them by the software 142 
utilized. Definitions for these variables are presented in Table 1. The six tasks are described 143 
below.   144 
Walk Across (Figure 1.): Patients walked across the long forceplate using their freely chosen 145 
standard gait speed and pattern.  146 
Weight Bearing Squat (Figure 2.): Patients stood still on the force plate and force was recorded 147 
with knee flexion angles of 0˚, 30˚, 60˚, and 90. The percentage of body weight on the involved 148 
limb was measured during a single trial with a duration .01s for each position.  A standard 149 
goniometer was used to verify knee joint angle at each position. 150 
Sit to Stand (Figure 3.): Patients were seated on a 50cm box.  Upon both visual and audio signal 151 
from the computer they rose to full standing as quickly as possible without using their hands, and 152 
then maintained a steady stance for the remainder of the 10 s trial.  153 
Step-Up/Over (Figure 4.): Participants stood behind a 29cm high box and stepped up onto the 154 
box with their test leg, then brought their non-test leg up and over the box, and then stepped 155 
down with their test leg. Patients were instructed to complete this task as quickly as possible 156 
while still maintaining control.  157 
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Forward Lunge: Patients in a standing position stepped forward on one leg and squatted down as 158 
far as possible, and then returned to the initial standing position as quickly as possible.  159 
Previous research has investigated the global components of function assessed by the 160 
long forceplate.  Using factor analysis methods, Chong identified the latent functional variables 161 
assessed in several of the included tasks.
34
  He concluded that the Sit to Stand assessed the 162 
underlying factors of both “agility” and “weight transfer”, the Step up/Over assessed “force 163 
control,” and the Forward Lunge assessed the underlying factor of “agility.”34  Additionally, 164 
Walk Across stride width and stride length evaluated “walking” factors not well represented in 165 
the other functional tasks.
34
  Outcomes utilizing the long forceplate have also previously been 166 
reported for postoperative recovery following total knee replacement.
19
  Finally, the long 167 
forecplate has been reported to be sensitive to functional deficits following anterior cruciate 168 
ligament reconstruction.
35
  This existing literature supports the use of the long forceplate as a 169 
useful tool for the assessment of lower extremity function, particularly among postoperative knee 170 
patients.   171 
Statistical Analysis 172 
 A mixed model analysis using a covariance pattern model with an autoregressive 173 
covariance matrix was used to compare changes in PROs and PBAs between preoperative, 3 174 
month, 6 month, and 12 month postoperative evaluations.  Significance level was set at p < 0.05 175 
a priori and when a main effect was significant, protected least significant difference pairwise 176 
comparisons were used to identify differences between individual time points.   177 
RESULTS 178 
 Six participants were declared clinical failures at or before the one year time point and 179 
were not medically cleared to complete functional testing at all follow-up time points; however 180 
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PRO scores were available for 4 of these patients who had yet to undergo reoperation at the one 181 
year time point.  An additional five participants were lost to follow-up.  All available data for all 182 
participants at all time points was incorporated into the statistical analysis. 183 
Patient Reported Outcomes 184 
 There was a main effect (p < 0.001) for time for all four PRO instruments (Figure 5).  185 
The WOMAC (p=0.050) was the only instrument to show significant changes between 186 
preoperation and the 3 month time point.  There were significant improvements from 187 
preoperation to the 6 and 12 month follow-ups for the IKDC (p < 0.001, p < 0.001, respectively), 188 
SF36-PCS (p = 0.002, p = 0.001), Lysholm (p < 0.001, p < 0.001), and WOMAC (p < 0.001, p < 189 
0.001).  190 
Performance Based Assessments 191 
 All PBAs demonstrated changes over time (Table 2.).  For the Walk Across task there 192 
was a significant increase in stride length observed at both the 6 and 12 month time points 193 
compared to preoperation (6 month, p = 0.002; 12 month, p= 0.005) and when compared to 3 194 
month values (6 month, p < 0.001; 12 month, p = 0.001).  There was no main effect for time for 195 
stride width (p= 0.663) or walking speed (p=.051).   196 
For the Weight Bearing Squat a main effect for time was observed for squatting at 30⁰ (p 197 
< 0.001), 60⁰, and 90⁰.  Post-hoc analyses revealed decreases in weight distribution on the 198 
surgical limb between preoperation (48% body weight) and 3 months (43% body weight, p = 199 
0.020) and 6 months (45% body weight, p = 0.020) for squatting at 30⁰.  Decreased weight 200 
bearing was also observed between preoperation and 3 months (p < 0.001) and preoperation and 201 
6 months (p = 0.048) for squatting at 60⁰.   Similarly, squatting weight distribution asymmetries 202 
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were observed at 90° relative to baseline at 3 months (p < 0.001) Although not statistically 203 
different from preoperative values, at the 12 month time point mean weight distributions 204 
remained below preoperative values at 30⁰, 60⁰, and 90⁰.   205 
The Sit to Stand demonstrated the earliest positive effects of surgery with decreased 206 
weight transfer time at 3 months (p=0. 016) compared to preoperation.  Weight transfer time 207 
continued to improve at 6 months (p=0.05) and 12 months (p=0.002).   208 
For the Step Up/Over there were significant increases in lift-up force between 209 
preoperation and the 3 (p=0.003), 6 (p = 0.005), and 12 (p=0.010) month follow-up time points. 210 
Time required to complete the Step Up/Over was also increased at 3months (p=0.009), but 211 
returned to baseline at later time points.  Similarly, Step Up/Over impact index was increased 212 
over preoperation values at 3 months (p=0.001) and 6 months (p=0.034), possibly demonstrating 213 
a loss of eccentric control when stepping down from the box.  214 
 Finally, results for the Forward Lunge showed a significant decrease in impact index 215 
(peak vertical ground reaction force) at 3 months (p = 0.007), but returned to preoperative levels 216 
and began to increase at the 6 and 12 month time points.  Similar to the Step Up/Over, Forward 217 
Lunge time was slower at the 3 month time point (p = 0.006) but gradually became quicker at 218 
subsequent evaluations. 219 
  220 
DISCUSSION 221 
 The primary purpose of this study was to provide a timeline for recovery that could be 222 
utilized by both patients and clinicians in managing expectations regarding postoperative 223 
recovery of function. A summary timeline of the functional recovery observed in the first year 224 
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following ACI can be seen in Figure 6.  Overall, these results suggest that patients may 225 
experience physical benefits such as decreased pain and symptoms as early as 3 months 226 
following ACI, but some facets of functional performance may initially decline following 227 
surgery, with significant improvements in functional performance of complex tasks such as 228 
squatting and stepping not occurring until 12 months, or perhaps longer.    229 
Patient Reported Outcomes 230 
PROs have frequently been utilized to document functional outcomes following ACI.
3-5
    231 
The observed results suggest that patients may experience functional improvements for simple 232 
activities of daily living tasks such as those evaluated by the WOMAC as early as 3 months 233 
following ACI.  However, data from the other self-reported outcome instruments utilized suggest 234 
that patients should not expect significant improvement prior to the 6 month time point.  The 235 
lack of significant improvement in most PRO scores at the 3 month time point is in agreement 236 
with previous research by Henderson and Levigne and Ebert et al. 
23, 36
   However,  both of these 237 
authors observed decreases in self-reported function using the IKDC
36
 and SF-36 PCS
23, 36
 at the 238 
three month time point, while we observed slight, but non-significant increases.   In contrast 239 
Tohyama et al. reported significant improvements in Lysholm scores as early as 3 months 240 
following treatment with atelocollagen-associated ACI.
37
 241 
The improvements observed among patients in IKDC, Lysholm, and SF-36 PCS scores at 242 
6 months were similar to the outcomes observed by Niemeyer et al. for the IKDC
38
 and both 243 
Niemeyer et al. and Kreuz et al. for the Lysholm.
38, 39
   Other authors have observed even larger 244 
improvements in IKDC
37
 and Lysholm
40
 scores as early as 6 months following ACI.   245 
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Across all PROs we observed improvements when preoperative scores were compared to 246 
scores 12 months following ACI surgery.  These results are in agreement with the findings of 247 
others when utilizing the IKDC,
36, 38, 39, 41-45
 Lysholm,
37-39, 41, 42
 SF-36 PCS,
36
 and WOMAC
46, 47
 248 
scores 1-year following ACI.  Regardless of which outcome instrument is used, the IKDC, 249 
Lysholm, SF-36 PCS, or the WOMAC, both clinicians and patients can anticipate improvements 250 
in self-perceived function during the first year following ACI. 251 
Performance Based Assessments 252 
 Limited improvements in PBAs were observed 1-year following ACI (Table 2.).  In 253 
general, a decrease in physical performance was observed at 3 and 6 months postoperatively, 254 
followed by a return towards baseline at 12 months following ACI.  This pattern of decreased 255 
function followed by gradual return/improvement of function was particularly true for the 256 
Weight Bearing Squat, Step Up/Over, and Lunge.  The only measures to show positive 257 
improvements from preoperative levels at or within the 12 month time period were Walk Across 258 
stride length , Sit to Stand weight shift time, and Step Up/Over lift-up index.  These results 259 
suggest that improvements for simpler, less demanding tasks, such as walking or going up steps 260 
can be seen as early as 6 to 12 months following ACI.  However, for more complex tasks, 261 
particularly those that require eccentric quadriceps control - such as squatting, going down steps, 262 
or lunging - meaningful changes in function may not be observed within the first year following 263 
ACI.   264 
 Decreases in physical performance at the 3 month time point have been previously 265 
observed with the 6 minute walk-test following matrix-induced autologous chondrocyte 266 
implantation (MACI)
23, 25
 and characterized chondrocyte implantation (CCI).
24
  Similar to our 267 
results, other researchers have observed slight improvements in walking performances at the 6 268 
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month
25
  and 12 month
24, 25
 time points that continue to improve at 24 month follow-up.
24, 25
  269 
During laboratory gait analysis, improvements in gait speed and stride length, without significant 270 
changes in stride width, were observed over 12 months following MACI.
48
  These results support 271 
our observation that, after an initial decrease in function, both patients and physicians can 272 
anticipate improvements in gait beginning around the 6 month time point following ACI. 273 
 In examining more dynamic tasks, Van Assche et al. observed deceased functional 274 
performance for a series of hopping and strength tasks (single-limb hop, cross-over hop, 6 m 275 
timed hop, and isometric knee extension strength) at 6 months following CCI and no significant 276 
improvements were observed as late as 24 months after CCI.
28
  For example, these authors 277 
observed a 9% decrease in the single-leg hopping limb symmetry index through 24 months 278 
following surgery.
28
  These results are in agreement with our observations demonstrating an 279 
initial decrease in function for more dynamic tasks such as squatting and stepping, with few or 280 
no significant or measurable improvements in functional performance at the 12 month time point 281 
following ACI.    282 
 In comparison to normative data
49
 it can be observed that some long forceplate variables 283 
are below preoperative levels at baseline, but approach or achieve age group normative values 284 
during the first year of postoperative recovery.  These include the Step Up/Over lift-up index and 285 
Forward Lunge distances.  However, other variables such as Step Up/Over and Forward Lunge 286 
times are below normal at baseline, become more abnormal at the three month time point and 287 
despite some improvement continue to be below normative levels at the one year mark.   These 288 
results suggest that although patients may have improvements in the ability to successfully 289 
perform the task, they continue to do so at a slower pace. 290 
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 Across the literature and within our study sample, improvements in gait relative to 291 
presurgery have been observed as early as 6 months following ACI.
25
  However, improvements 292 
in more dynamic activities such as squatting, lunging, stepping, and hopping have not been 293 
observed within the first 12 months following ACI in the present study or elsewhere.
28
  These 294 
results support existing theory that although improvements in self-report measures may occur 295 
early postoperatively, maximal defect healing and functional improvement continues beyond 12 296 
months following ACI. 
50-53
  297 
 The occurrence of changes in self-report measures of function prior to changes in 298 
performance based measures of function may be a result of the large influence pain levels have 299 
been observed to have on PRO scores.
19-22
  The observed improvement in PRO scores in the 300 
absence of improved physical performance supports the importance of incorporating both types 301 
of outcome measures when documenting patient outcomes.  The importance of a patient’s own 302 
rating of function and subjective feelings towards joint health cannot be ignored.  However, 303 
when considering decisions such as ability to return to work or physical activity, or to evaluate 304 
postoperative changes in biomechanics, performance based measures provide unique information 305 
that cannot be fully and accurately captured by PROs along. 306 
Limitations 307 
 A limitation of this study is the inclusion of a diverse ACI patient population.  The study 308 
sample included individuals undergoing treatment for lesions to the patella, trochlea, and/or 309 
femoral condyle many of which also underwent concomitant realignment procedures.  310 
Additionally, rehabilitation compliance was not tracked, and all patients were free to work with a 311 
physical therapist of their choice.  Because of this variability, the presented timeline for recovery 312 
is not specific or precise for any one defect location and/or realignment procedure.  Instead a 313 
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broad pattern of recovery has been presented that can be generalized to a variety of defect 314 
patterns and sizes. 315 
 An additional limitation of this study is the lack of outcomes beyond 12 months post-316 
ACI.  However, the purpose of this study was to provide a descriptive time line for changes in 317 
self-perceived function and functional recovery in the first year following ACI.  This time line is 318 
intended to describe when patients can expect improvements in activities of daily living and 319 
when patients will perceive a benefit from the surgery, two key pieces of information that may 320 
be valuable to patients and physicians when deciding if and when to undergo ACI.  Future 321 
examination of these outcome variables for a longer period (> 1 year) will provide more 322 
information regarding the long term course of recovery following ACI.   323 
 324 
CONCLUSIONS 325 
 This study presents a descriptive timeline for changes in both PROs and PBAs during the 326 
first 12 months following ACI.  Self-perceived changes in function were observed as early as 3 327 
months following ACI while performance based measures of function demonstrated functional 328 
deficits compared to preoperative levels at both the 3 and 6 month time points.  Specifically, 329 
patients demonstrated increased asymmetry of weight distribution when squatting and rising 330 
from sitting, decreased vertical ground reaction force production during lunging, and longer 331 
performance times for lunging and stepping activities.  At the 12 month time point performance 332 
improvements were seen for walking speed, Sit to Stand weight transfer time and Step Up/Over 333 
lift-up index: however, Step Up/Over time and Forward Lunge impact index and time remained 334 
below previously reported norms.  Overall, it was observed that patients’ perceptions of 335 
functional improvements may outpace true physical changes in function.  The present results, 336 
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combined with those in the literature provide important information for both physicians and 337 
rehabilitation specialists to consider when working with cartilage patients who desire to return to 338 
high level physical activity.  Clearly, recovery can be lengthy, and intense rehabilitation (beyond 339 
the existing standard of care) may be necessary to improve beyond or even restore dynamic 340 
function to preoperative levels. 341 
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Table 1. Functional tasks evaluated on the NeuroCom Balance Master ® Long 513 
Force Plate.  All tasks were performed in the order presented by patients treated for articular 514 
cartilage defects to the knee. 515 
Task Parameter(s) 
Assessed 
NeuroCom Outcome 
Variable 
Definition 
Walk 
Across 
Characterizati
on of Gait 
Stride Length (cm) Distance between contralateral heel strikes  
  Stride Width (cm) Lateral distance between center of pressure of 
left and right foot strikes 
  Walking Speed (cm/s) Speed of forward progression of the center of 
gravity (COG) 
Weigh
t Bearing 
Squat 
Strength, 
Weight Distribution 
% Body Weight (BW) 
at 0° (full extension), 30°, 
60°, and 90° of knee 
flexion 
% BW on the involved limb at each position 
(test duration .01s) 
Sit To 
Stand 
Strength, 
Weight Distribution, 
Performance Time, 
Double Limb 
Balance 
Weight Transfer time 
(s) 
Time required from start of motion while sitting 
(i.e. increase in center of pressure(COP) forward 
velocity by 5% from resting velocity) to achieve full 
weight bearing standing (i.e. forward velocity drops 
to within 5% of standing resting velocity) 
  Rising Index (%BW) Peak vertical force exerted through the legs 
when rising to full standing relative to stationary 
vertical standing force 
  Weight Symmetry % Difference in weight supported by each limb 
during the weight transfer phase 
Step-
up/Over 
Concentric 
Strength, Eccentric 
Control, 
Performance Time 
Lift-up Index (%BW) Peak vertical force occurring while stepping up 
onto the box as a percentage of body weight 
 Impact Index (%BW) Peak vertical force occurring while stepping 
down off the box as a percentage of body weight 
  Movement Time (s) Time between initial weight shift (i.e. change in 
COP velocity by 5%) and contact with force plate 
on opposite side of box (determined by COP 
velocity dropping to within 5% of post-test resting 
velocity) 
Lunge Concentric 
and Eccentric 
Control, Functional 
Range of Motion, 
Performance Time 
Distance (% subject 
height) 
Length of lunge step as a percentage of 
subject height 
 Movement Time (s) Duration of lunge phase during which lead leg 
is in contact with the force plate. Start and stop of a 
trial is determined by 5% change in COP velocity 
from pre-test and post-test resting velocity. 
  Impact Index (%BW) Peak vertical force occurring during lunge 
maneuver as a percentage of body weight 
 516 
 517 
 518 
 519 
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 520 
 521 
Table 2. Patient Reported and Performance Based Assessments Over 12 Months Following Autologous 
Chondrocyte Implantation  
 Test 
  
Preoperati
ve 
3 Months 6 Months 12 Months 
 Variable Mean (SD) Mean(SD) Mean (SD) Mean (SD) 
Walk Across           
 Width (% height) 
1
0.1 
(2.8
) 
9
.7 (2.5) 9.7 (2.1) 9.5 (2.5) 
 Length (%height) 
4
2.0 
(8.9
) 
4
2.1 (10.5) 
46.
8 (8.1)*
†
 
46.
9 
(7.6)*
†
 
 Speed (cm/s) 
8
2.6 
(16.
8) 
8
7.7 (24.6) 
88.
2 (19.3) 
94.
5 (18.2)
 
 
Double Limb Squat (% Body Weight (BW))         
 0⁰ 
4
8 (5) 
4
8 (3) 49 (3) 49 (5) 
 30⁰ 
4
8 (8) 
4
3 (6)* 45 (6)* 46 (5) 
 60⁰ 
4
7 (8) 
4
2 (7)* 44 (6)* 45 (6)
† 
 90⁰ 
4
8 (6)
 †
 
4
4 (5)* 
46
† 
(6) 46 (6)
 †
 
Sit to Stand           
 Weight Transfer Time (s) 
0.
51 
(0.2
6) 
0
.39 (0.32)
* 
0.3
6 (0.19)
* 
0.3
3 
(0.20)
* 
 Rise Index (% BW>100%)  
2
3.3 
(9.4
) 
2
2.0 (8.5) 
24.
0 (8.4) 
24.
6 (8.8) 
 
Inv/Uninv Symmetry (-towards 
uninvolved) 
-
6.24 
(17.
6) 
-
13.7 (15.2)
* 
-
9.9 (9.8) 
-
8.37 (12.3) 
Step Up/Over           
 Lift-up Index (% BW>100%) 
4
1.0 
(11.
3) 
4
5.0 (11.7)
* 
47.
0 (11.3)
*  
47.
3 
(11.6)
*  
 Time (s) 
1.
49 
(0.3
3)
† 
1
.67 (0.69)
* 
 
1.5
1 
(0.36)
 
†
 
1.4
0 
(0.26)
 
†
 
 Impact (% BW) 
4
7.6 
(17.
0)
† 
5
4.9 (18.2)
* 
54.
1 (19.3)
* 
50.
7 (16.9) 
Forward Lunge           
 Distance (% height) 
4
4.9 
(7.1
) 
4
6.8 (19.1) 
50.
5 (19.0)
 
51.
3
 
(23.8)
 
 
 Impact Index (% BW) 
2
4.4 
(7.0
)
†
 
2
1.8 (6.7)
* 
 
24.
4 (7.4)
 †
 
27.
2 
(10.4)
 
†
 
 Time (s) 
1.
39 (0.43)
†
 
1
.51 (0.44)
* 
1.3
4 
(0.28)
†
 
1.2
9 
(0.39)
†
 
Patient Reported Outcomes           
 IKDC 
3
8.43 (12.5) 
4
1.62 
(15.68
) 
51.
10 
(18.34
)*
†
 
56.
21 
(20.6
4) *
†
 
 SF-36 PCS 
3
7.39 (8.79) 
3
7.98 (9.83) 
43.
50 
(9.16)
*
†
 
44.
22 
(11.2
8) *
†
 
 Lysholm 
4
7 (18) 
5
4 (21) 61 (23) *
†
 65 
(24) 
*
†
 
  WOMAC 
3
3 (17)
† 
2
8 (17)
* 
22 (19) *
†
 20 
(19) 
*
†
 
*significantly different from preoperative time point, †significantly different from 3 month time point,  
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Figure 1. Walk Across 522 
 523 
Walk Across outcome variables included stride width, stride length, and speed 524 
 525 
Figure 2. Weight Bearing Squat 526 
 527 
Percentage of body weight on the involved limb was evaluated at 0 (not pictured), 30, 60 and 528 
90 degrees of knee flexion. 529 
 530 
531 
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 532 
Figure 3. Sit to Stand 533 
 534 
Sit to Stand: Beginning from a sitting position, upon receiving a visual and audio cue 535 
participants were instructed to rise from sitting as quickly as possible without using hands to 536 
push off the box. Outcome   measures included weight transfer time, rising index and weight 537 
symmetry. 538 
 539 
Figure 4.  Step Up/Over 540 
 541 
Step Up/Over: Beginning with both feet behind the box, participants were instructed to step 542 
up and over the box and return to stationary standing as quickly as they could do so while still 543 
maintaining control.  Outcome variables were lift-up index, impact index, and movement time. 544 
 545 
 546 
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Figure 5. Patient Reported Outcome Scores  547 
 548 
*p < 0.05 compared to preoperative time point.  IKDC and Lysholm are scored from 0 to 549 
100 with 100 representing an ideal score.  SF-36 PCS uses norm based scoring system 550 
where 50 represents a mean score with a standard deviation of 10 and higher scores 551 
representing higher levels of function.  The WOMAC is scored 96-0 with 0 representing no 552 
disability.  Error bars represent standard deviation. 553 
 554 
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Figure 6. Timeline of Functional Recovery Following Autologous Chondrocyte 555 
Implantation                556 
 557 
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